John Sourbeer
Stock Analyst at UBS
(1.45)
# 1,451
Out of 4,479 analysts
33
Total ratings
50%
Success rate
-16.4%
Average return
Main Sectors:
15 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OMIC Singular Genomics Systems | Maintains: Neutral | $12 → $15 | $8.52 | +76.06% | 2 | Mar 20, 2024 | |
| CYRX Cryoport | Maintains: Neutral | $15 → $17 | $6.39 | +166.04% | 4 | Mar 15, 2024 | |
| MEDP Medpace Holdings | Maintains: Buy | $452 → $480 | $407.24 | +17.87% | 4 | Mar 8, 2024 | |
| AKYA Akoya Biosciences | Maintains: Buy | $7 → $7.5 | $2.21 | +239.37% | 2 | Mar 5, 2024 | |
| QDEL QuidelOrtho | Downgrades: Sell | $70 → $42 | $31.63 | +32.79% | 1 | Mar 4, 2024 | |
| BRKR Bruker | Maintains: Buy | $94 → $102 | $62.33 | +63.65% | 3 | Mar 1, 2024 | |
| WST West Pharmaceutical Services | Maintains: Neutral | $400 → $375 | $324.55 | +15.54% | 2 | Feb 16, 2024 | |
| PACB Pacific Biosciences of California | Maintains: Buy | $13 → $12 | $1.20 | +900.00% | 2 | Feb 16, 2024 | |
| CTLT Catalent | Downgrades: Neutral | $58 → $64 | $56.16 | +13.07% | 4 | Feb 6, 2024 | |
| QGEN Qiagen | Maintains: Neutral | $49 → $43 | $40.23 | +7.53% | 3 | Nov 2, 2023 | |
| ILMN Illumina | Maintains: Neutral | $255 → $240 | $105.50 | +127.49% | 1 | Feb 14, 2023 | |
| TXG 10x Genomics | Initiates: Neutral | $50 | $18.59 | +168.96% | 1 | Feb 2, 2023 | |
| ICLR ICON PLC | Initiates: Buy | $270 | $316.51 | -14.69% | 1 | Sep 7, 2022 | |
| ABT Abbott Laboratories | Maintains: Buy | $142 → $128 | $103.20 | +24.03% | 2 | Jul 27, 2022 | |
| STVN Stevanato Group | Initiates: Neutral | n/a | $18.73 | - | 1 | Aug 10, 2021 |
Singular Genomics Systems
Mar 20, 2024
Maintains: Neutral
Price Target: $12 → $15
Current: $8.52
Upside: +76.06%
Cryoport
Mar 15, 2024
Maintains: Neutral
Price Target: $15 → $17
Current: $6.39
Upside: +166.04%
Medpace Holdings
Mar 8, 2024
Maintains: Buy
Price Target: $452 → $480
Current: $407.24
Upside: +17.87%
Akoya Biosciences
Mar 5, 2024
Maintains: Buy
Price Target: $7 → $7.5
Current: $2.21
Upside: +239.37%
QuidelOrtho
Mar 4, 2024
Downgrades: Sell
Price Target: $70 → $42
Current: $31.63
Upside: +32.79%
Bruker
Mar 1, 2024
Maintains: Buy
Price Target: $94 → $102
Current: $62.33
Upside: +63.65%
West Pharmaceutical Services
Feb 16, 2024
Maintains: Neutral
Price Target: $400 → $375
Current: $324.55
Upside: +15.54%
Pacific Biosciences of California
Feb 16, 2024
Maintains: Buy
Price Target: $13 → $12
Current: $1.20
Upside: +900.00%
Catalent
Feb 6, 2024
Downgrades: Neutral
Price Target: $58 → $64
Current: $56.16
Upside: +13.07%
Qiagen
Nov 2, 2023
Maintains: Neutral
Price Target: $49 → $43
Current: $40.23
Upside: +7.53%
Illumina
Feb 14, 2023
Maintains: Neutral
Price Target: $255 → $240
Current: $105.50
Upside: +127.49%
10x Genomics
Feb 2, 2023
Initiates: Neutral
Price Target: $50
Current: $18.59
Upside: +168.96%
ICON PLC
Sep 7, 2022
Initiates: Buy
Price Target: $270
Current: $316.51
Upside: -14.69%
Abbott Laboratories
Jul 27, 2022
Maintains: Buy
Price Target: $142 → $128
Current: $103.20
Upside: +24.03%
Stevanato Group
Aug 10, 2021
Initiates: Neutral
Price Target: n/a
Current: $18.73
Upside: -